Celularity Share Price Today
(NASDAQ: CELU)

Name: Celularity Share Price Today (NASDAQ: CELU) - Celularity Stock Price Live Quote | INDmoney
Brand: INDmoney
Rating: 4.7 (371551 reviews)

Celularity share price is $1.37 & ₹119.15 as on 6 Mar 2025, 2.30 'hrs' IST

$1.37

▲

0.29

(26.85%)

Market is closed - opens 8 PM, 06 Mar 2025

View live Celularity share price in Dollar and Rupees. Guide to invest in Celularity stock from India, including Indian investor sentiment. Get details on Indian mutual funds investing in Celularity, along with analyst recommendations, forecasts, and comprehensive financials.

Celularity share price movements

Today's Low: $1.17
Today's High: $1.56
$1.37
14.59%
Downside
Day's Volatility :24.93%
Upside
12.11%
52 Weeks Low: $1.00
52 Weeks High: $7.97
$1.37
26.96%
Downside
52 Weeks Volatility :87.44%
Upside
82.81%

Celularity (CELU) Returns

Period	Celularity Inc	Sector (Health Care)	Index (Russel 2000)
3 Months	-40.95%	3.7%	0.0%
6 Months	-51.76%	-2.8%	0.0%
1 Year	-68.14%	2.5%	0.0%
3 Years	-98.26%	12.9%	-11.6%

Celularity (CELU) Key Statistics

in dollars & INR

Previous Close	$1.08
Open	$1.2
Today's High	$1.5587
Today's Low	$1.1701
Market Capitalization	$25.7M
Today's Volume	$890.3K
52 Week High	$7.97
52 Week Low	$1.0007
Revenue TTM	$48.2M
EBITDA	$-31.6M
Earnings Per Share (EPS)	$-91.88
Profit Margin	-72.72%
Quarterly Earnings Growth YOY	-0.61%
Return On Equity TTM	-147.5%

How to invest in Celularity Stock (CELU) from India?

It is very easy for Indian residents to invest directly in Celularity from India. Indian investors can open a free US stocks account on the INDmoney app. You can find live prices of the Celularity stock in both Indian Rupees (INR) and US Dollars (USD). Search for Celularity or CELU on the INDmoney app and click on Buy or SIP. You can invest by choosing quantities of shares of Celularity or rupee/ dollar value or set up a fixed SIP amount to be invested every month or week.

For example: You can easily buy Rs.100 worth of Celularity shares which would translate to 0.635 fractional shares of Celularity as of today. Learn more about fractional investing.

Indians can now also easily transfer and add money to their US stocks account via the INDmoney app. Invest in US Stocks from India, including recognised companies like Celularity, in just a few clicks!

Returns in Celularity (CELU) for Indian investors in Rupees

The Celularity stock calculator helps Indian investors calculate returns based on the historical performance of the stock. Just choose your investment amount and duration to get insights and invest more confidently. See stock returns as well as the effect of dollar appreciation over different durations.

Investment Value

₹1,00,000

Celularity investment value today

Current value as on today

₹36,809

Returns

₹63,191

(-63.19%)

Returns from Celularity Stock

₹68,140 (-68.14%)

Dollar Returns

₹4,949 (+4.95%)

Indian investors sentiment towards Celularity (CELU)

275%

Period: Feb 3, 2025 to Mar 5, 2025. Change in 30 Days versus previous period

Search interest for Celularity Stock from India on INDmoney has increased by 275% in the last 30 days, reflecting an upward trend in search activity.

Global Institutional Holdings in Celularity

C V Starr & Co Inc
3.21%
Vanguard Group Inc
2.10%
Geode Capital Management, LLC
0.55%
BlackRock Inc
0.43%
State Street Corp
0.27%
Two Sigma Investments LLC
0.19%

Analyst Recommendation on Celularity

Buy

85%Buy

14%Hold

0%Sell

Based on 7 Wall street analysts offering stock ratings for Celularity(by analysts ranked 0 to 5 stars)

Based on 7 analyst

Current
1M Ago
3M Ago

Buy

Hold

Sell

Analyst Forecast on Celularity Stock (CELU)

What analysts predicted

Upside of 82.48%

Target:

$2.50

Current:

$1.37

Insights on Celularity Stock (Ticker Symbol: CELU)

Price Movement
In the last 7 days, CELU stock has moved up by 12.3%
Decreasing Revenue
Revenue is down for the last 3 quarters, 14.68M → 9.29M (in $), with an average decrease of 20.4% per quarter
Decreasing Net Profit
Netprofit is down for the last 2 quarters, 9.54M → -16.09M (in $), with an average decrease of 268.6% per quarter
CELU vs ALNY (1 yr)
In the last 1 year, Alnylam Pharmaceuticals, Inc. has given 66.5% return, outperforming this stock by 134.6%
CELU vs VRTX (3 yr)
In the last 3 years, Vertex Pharmaceuticals Incorporated has given 51.6% return, outperforming this stock by 149.6%
Price to Sales
ForCELU every $1 of sales, investors are willing to pay $0.6, whereas for Alnylam Pharmaceuticals, Inc., the investors are paying $14.2 for every $1 of sales.

CELU Celularity Financials in INR & Dollars

	FY19	Y/Y Change
Revenue	$21.1M	-
Net Income	$5.9M	-
Net Profit Margin	27.8%	-

	FY20	Y/Y Change
Revenue	$14.3M	↓ 32.48%
Net Income	$-208.2M	↓ 3642.12%
Net Profit Margin	-1.5K%	↓ 1486.22%

	FY21	Y/Y Change
Revenue	$21.3M	↑ 49.43%
Net Income	$-100.1M	↓ 51.92%
Net Profit Margin	-469.27%	↑ 989.15%

	FY22	Y/Y Change
Revenue	$18.0M	↓ 15.75%
Net Income	$14.2M	↓ 114.18%
Net Profit Margin	78.95%	↑ 548.22%

	FY23	Y/Y Change
Revenue	$22.8M	↑ 26.68%
Net Income	$-196.3M	↓ 1483.14%
Net Profit Margin	-862.04%	↓ 940.99%

	FY24	Y/Y Change
Revenue	$22.8M	↑ 0.0%
Net Income	$-196.3M	↑ 0.0%
Net Profit Margin	-862.04%	↑ 0.0%

	Q2 FY23	Q/Q Change
Revenue	$2.9M	↓ 25.34%
Net Income	$-47.9M	↓ 25.1%
Net Profit Margin	-1.6K%	↓ 5.17%

	Q3 FY23	Q/Q Change
Revenue	$3.8M	↑ 28.86%
Net Income	$-93.9M	↑ 95.78%
Net Profit Margin	-2.5K%	↓ 847.53%

	Q4 FY23	Q/Q Change
Revenue	$3.8M	↑ 0.0%
Net Income	$-93.9M	↑ 0.0%
Net Profit Margin	-2.5K%	↑ 0.0%

	Q1 FY24	Q/Q Change
Revenue	$14.7M	↑ 287.77%
Net Income	$-22.0M	↓ 76.55%
Net Profit Margin	-149.94%	↑ 2329.62%

	Q2 FY24	Q/Q Change
Revenue	$12.1M	↓ 17.5%
Net Income	$9.5M	↓ 143.37%
Net Profit Margin	78.82%	↑ 228.76%

	Q3 FY24	Q/Q Change
Revenue	$9.3M	↓ 23.25%
Net Income	$-16.1M	↓ 268.62%
Net Profit Margin	-173.17%	↓ 251.99%

	FY19	Y/Y Change
Profit	$14.8M	-

	FY20	Y/Y Change
Profit	$9.3M	↓ 36.95%

	FY21	Y/Y Change
Profit	$11.7M	↑ 24.99%

	FY22	Y/Y Change
Profit	$-1.7M	↓ 114.47%

	FY23	Y/Y Change
Profit	$6.8M	↓ 499.7%

	FY24	Y/Y Change
Profit	$6.8M	↑ 0.0%

	Q2 FY23	Q/Q Change
Profit	$1.9M	↓ 108.71%

	Q3 FY23	Q/Q Change
Profit	$184.0K	↓ 90.28%

	Q4 FY23	Q/Q Change
Profit	$184.0K	↑ 0.0%

	Q1 FY24	Q/Q Change
Profit	$13.0M	↑ 6987.5%

	Q2 FY24	Q/Q Change
Profit	$2.5M	↓ 80.81%

	Q3 FY24	Q/Q Change
Profit	$5.4M	↑ 116.26%

	FY19	Y/Y Change
Operating Cash Flow	$-1.1M	↓ 98.17%
Investing Cash Flow	$-31.5M	↑ 0.93%
Financing Cash Flow	$288.8M	↑ 272.46%

	FY20	Y/Y Change
Operating Cash Flow	$-63.2M	↑ 5656.16%
Investing Cash Flow	$578.7K	↓ 101.84%
Financing Cash Flow	$102.0M	↓ 64.68%

	FY21	Y/Y Change
Operating Cash Flow	$-110.1M	↑ 74.22%
Investing Cash Flow	$-5.9M	↓ 1120.04%
Financing Cash Flow	$98.6M	↓ 3.38%

	FY22	Y/Y Change
Operating Cash Flow	$-137.9M	↑ 25.23%
Investing Cash Flow	$-5.2M	↓ 11.3%
Financing Cash Flow	$119.8M	↑ 21.59%

	Q2 FY23	Q/Q Change
Operating Cash Flow	$-11.0M	↓ 26.46%
Investing Cash Flow	$-31.0K	↓ 99.03%
Financing Cash Flow	$5.6M	↓ 56.03%

Celularity Technicals Summary

Sell

Neutral

Buy

Celularity is currently in a neutral trading position according to technical analysis indicators.

Celularity (CELU) Vs Peers

Company Name	1 Month	6 Month	1 Year	3 Years	5 Years
Celularity Inc	-31.16%	-51.76%	-68.14%	-98.26%	-86.49%
Regeneron Pharmaceuticals, Inc.	-1.42%	-40.28%	-29.31%	11.08%	44.83%
Beone Medicines Ltd	17.63%	36.87%	64.37%	45.89%	71.3%
Vertex Pharmaceuticals Incorporated	1.94%	4.92%	19.37%	108.73%	123.83%
Alnylam Pharmaceuticals, Inc.	-8.03%	-0.89%	66.53%	52.9%	126.66%

Company Name	P/E Ratio	P/B Ratio	PEG Ratio	EPS	ROE	ROA	Div Yield	BVPS
Celularity Inc	2.28	NA	NA	0.0	-1.47	-0.17	NA	0.79
Regeneron Pharmaceuticals, Inc.	17.86	17.86	1.01	43.09	0.16	0.07	0.01	273.57
Beone Medicines Ltd	NA	NA	NA	1.43	-0.19	-0.06	NA	31.22
Vertex Pharmaceuticals Incorporated	32.84	NA	1.34	18.07	-0.03	0.13	NA	63.87
Alnylam Pharmaceuticals, Inc.	NA	NA	-0.49	0.57	-15.01	-0.03	NA	0.52

Company Name	Analyst View	Market Cap	5 Years Return %	PE Ratio	Profit Margin
Celularity Inc	Buy	$25.7M	-86.49%	2.28	-72.72%
Regeneron Pharmaceuticals, Inc.	Buy	$73.8B	44.83%	17.86	31.07%
Beone Medicines Ltd	NA	$29.1B	71.3%	NA	-16.92%
Vertex Pharmaceuticals Incorporated	Buy	$124.9B	123.83%	32.84	-4.86%
Alnylam Pharmaceuticals, Inc.	Buy	$31.4B	126.66%	NA	-12.37%

About Celularity

Celularity Inc., a clinical-stage biotechnology company, develops off-the-shelf placental-derived allogeneic cell therapies for the treatment of cancer, immune, and infectious diseases. The company operates through Cell Therapy, Degenerative Disease, and BioBanking segments. Its lead therapeutic programs include CYCART-19, an allogeneic CAR-T cell for the treatment of non-Hodkin's lymphoma (NHL) and mantle cell lymphoma (MCL); CYNK-001, an allogeneic unmodified natural killer cell that is in Phase I/II clinical trial for the treatment of acute myeloid leukemia (AML); and APPL-001, a genetically modified placental-derived mesenchymal-like adherent stromal cell for the treatment of Crohn's disease. In addition, the company is developing CYCART-201 for the treatment of NHL and MCL, and human epidermal growth factor receptor 2 positive cancers; CYNK-301, a next generation chimeric antigen receptor-natural killer (CAR-NK) for treating relapse refractory AML; CYNK-302, a CAR-NK to treat non-small cell lung cancer; and pExo-001, a human postpartum placenta derived exosome product for the treatment of osteoarthritis. Celularity Inc. produces, sells, and licenses products that are used in surgical and wound care markets, such as Biovance, Biovance 3L, Interfyl, and Centaflex; and collects and stores stem cells from umbilical cords and placentas under the LifebankUSA brand. The company has licensing agreement with Sorrento Therapeutics, Inc. for the development and commercialization of licensed CD19 CAR-T products; research collaboration services agreement with Regeneron Pharmaceuticals, Inc. to support the research of allogeneic cell therapy candidates; and a collaboration agreement with BlueSphere Bio, Inc. covering manufacturing activities for certain cell therapy products. Celularity Inc. was founded in 1998 and is based in Florham Park, New Jersey.

Organization	Celularity
Employees	120
CEO	Dr. Robert Joseph Hariri M.D., Ph.D.
Industry	Healthcare

Management People of Celularity

Name	Title
Dr. Robert Joseph Hariri M.D., Ph.D.	Founder, CEO & Chairman
Mr. David C. Beers C.F.A.	Chief Financial Officer
Mr. John R. Haines	Senior EVP, Corporate Secretary, Global Manager & Chief Administrative Officer
Mr. Carlos Ramirez	SVP of Investor Relations
Dr. Stephen A. Brigido D.P.M.	President of Degenerative Diseases
Sharmila Koppisetti M.D.	Senior Vice President of Clinical Dev. Immunology & Drug Safety
Mr. Tim Wilk	Senior Vice President of Technical Operations
Mr. David Jakob Lemus CPA, M.S., MBA	Treasurer

Important FAQs about investing in CELU Stock from India :

What is Celularity share price today?

Celularity share price today stands at $1.37, Open: $1.20 ; Previous Close: $1.08 ; High: $1.56 ; Low: $1.17 ; 52 Week High: $7.97 ; 52 Week Low: $1.00.

The stock opens at $1.20, after a previous close of $1.08. The stock reached a daily high of $1.56 and a low of $1.17, with a 52-week high of $7.97 and a 52-week low of $1.00.

Can Indians buy Celularity shares?

Yes, Indians can invest in the Celularity (CELU) from India.

With INDmoney, you can buy Celularity at 0 brokerage. The step-by-step process is as follows:

Open your zero cost US Stocks account and zero balance IND linked savings a/c (this can be done in less than 3 minutes)
Transfer funds to your US Stocks account using your IND linked savings a/c (It takes 24 hours excluding Saturday and Sunday). With INDmoney, you get the best INR USD exchange rates.
Once funds are transferred successfully, you can buy Celularity at zero transaction cost.

How can I buy Celularity shares from India?

It is very easy to buy Celularity from India. With INDmoney, you can open a US stocks account in less than 3 minutes. Transfer funds in 24 hours and buy stocks very easily - that too at 0 brokerage. All this is done at 0 account opening & management fee, 0 brokerages, and at the same time you get the best rupee-US dollar exchange rate.

Can Fractional shares of Celularity (CELU) be purchased?

Yes, you can buy fractional shares of Celularity with INDmoney app.

What are the documents required to start investing in Celularity stocks?

To start investing in Celularity, You will need the following documents:

Proof of Identification (PAN, Aadhaar etc)
Proof of address (Aadhaar, Voter ID etc)

These documents are required as per RBI's guidelines to create your IND linked savings a/c so that you can execute for global fund transfer. The entire process is paperless and can be completed seamlessly.